Devices & Diagnostics

Spirox closes $45M Series C for its device used by Ear, Nose and Throat physicians

Nasal obstruction is a significant problem that effects more than three million Americans each year. Spirox is developing a minimally invasive device that would decrease the need for surgery.

Spirox

California-based Spirox Inc. announced today that it has finalized a $45 million Series C round of financing, which will be used to move forward with its minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plastic surgeons to treat patients with nasal obstruction.

Nasal obstruction is a significant problem that effects more than three million Americans each year. Generally, surgical procedures are performed to treat deviated septums, reduce the size of turbinates or prevent nasal valve collapse. But surgery increases morbidity, which makes it a last resort type of procedure.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Spirox is looking to make treating these conditions with a minimally invasive approach possible with its device.

The financing round was led by global investment firm KKR as well as HealthQuest Capital, Aisling Capital, Aperture Venture Partners and Venrock.